Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.

Source:http://linkedlifedata.com/resource/pubmed/id/17363536

Clin. Cancer Res. 2007 Mar 15 13 6 1801-9

Download in:

View as

Triples

General Info

PMID
17363536